After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.

ASP3082 grabs some early attention among degraders set to feature at ESMO.

Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.

Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.

More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.

The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.

Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.